News
GSK shares fall after FDA panel votes against Blenrep combinations for myeloma
Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab mafodotin-blmf) combinations for treating relapsed or refractory multiple myeloma.
The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...
GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback